Analyzing 368 patients, the study was the largest to test hydroxychloroquine’s effects against COVID-19 and found that the two primary outcomes for patients treated with the drug were death and the need for mechanical ventilation.
The analysis was conducted retrospectively and was based on data from patients hospitalized with confirmed COVID-19 cases in all VA hospitals through April 11, The Hill reported. It was submitted for publication in The New England Journal of Medicine but has not yet been peer-reviewed.
Of the 368 patients involved, 97 were treated with hydroxychloroquine alone, 113 were given a combination of hydroxychloroquine and the antibiotic azithromycin, and the rest were given neither.
According to the study, 28 percent of patients who were given hydroxychloroquine plus routine care died versus 11 percent of those given routine care without the drug, The Hill reported.
The researchers noted that hydroxychloroquine was more likely to be prescribed to patients with severe COVID-19 cases, so increased mortality rates were to be expected, but that the high mortality rates in the hydroxychloroquine-only group persisted even after adjusting for that fact.
Read the full article here.
More articles on pharmacy:
CVS, UCLA Health unite to free hospital beds for COVID-19 patients
NIH teams up with 16 drugmakers to speed COVID-19 vaccine development
16 recent drug, device recalls
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.